Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug Doxil.

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Quick Links

 

Market News

Today's picks- 30 September 2014

Nifty, Bank Nifty, HCL Tech & IDFC

Untimely rainfall in Punjab affects cotton arrival in mandis

In crop year 2013-14 , raw cotton in Punjab was sold in the range of Rs 4,650-Rs 4,725 a quintal (on an average)

LLPs can be admitted as sub-brokers, says Sebi

The matter was clarified by the stock market regulator following an exchange query

Markets end flat; Sensex snaps 7-month rally

Markets ended flat shrugging off RBI's neutral stance on key policy rates

RBI takes small steps to deepen markets

The central bank said it will cut the HTM ceiling on bonds from the current 24% to 22%

Back to Top